Anthony Tolcher

Board member
Board of Directors
symphogen
Denmark

Business Expert Nephrology
Biography

 Dr. Tolcher is a medical oncologist with over 20 years' experience in early drug development and clinical trials. He has been involved in many of the initial studies of new agents that were subsequently FDA approved for the treatment of cancer including Keytruda® (pembroli- zumab), Kadcyla® (trastuzumab emtansine), Stivarga® (regorafenib), Marqibo® (liposomal vincristine), Jevtana® (cabazitaxel), Kyprolis® (carfilzomib), Iressa® (gefitinib), Tarceva® (erlotinib), and Halaven® (eribulin). He has chaired the Developmental Therapeutics Review Committee for the American Association of Clinical Oncology Annual Scientific Program and is on many pharmaceutical company scientific advisory boards. Dr. Tolcher is the president and co-founder of the START clinic in Texas, the US. Dr. Tolcher serves as a member of Symphogen's  Development Committee.

Research Intrest

 Drug development and clinical trials